Understanding SNORD92: A Potential Drug Target and Biomarker (G692209)

Target Name: SNORD92

NCBI ID: G692209

SNORD92

Other Name(s): HBII-316 | Small nucleolar RNA, C/D box 92 | small nucleolar RNA, C/D box 92

Understanding SNORD92: A Potential Drug Target and Biomarker

SNORD92 (HBII-316) is a novel protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has generated a lot of interest in the scientific community.

SNORD92 is a protein that is expressed in many different tissues and cells in the body, including the brain, heart, liver, and muscle. Its name comes from its structure, which is similar to that of a sodium channel. This structure allows SNORD92 to conduct electrical signals in the brain and other tissues, which is important for its function.

SNORD92 is involved in many different processes in the body, including the regulation of ion channels, neurotransmitter signaling, and cell signaling. It has been shown to play a role in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is also involved in the regulation of pain perception and has been shown to play a role in the development of chronic pain.

In addition to its potential role in neurodegenerative diseases, SNORD92 has also been shown to be involved in the regulation of cancer cell growth and survival. It has been shown to promote the growth and survival of cancer cells, which could make it an attractive target for cancer therapies.

SNORD92's unique structure and function have also made it an attractive target for the development of biomarkers. Its expression is regulated in many different tissues and cells, which makes it a potential biomarker for a variety of diseases. Its expression has been shown to be associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an important tool for the development of new diagnostic tests and therapies.

In conclusion, SNORD92 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its unique structure and function make it an attractive target for researchers to investigate, and its potential as a drug or biomarker has generated a lot of interest in the scientific community. Further research is needed to fully understand its role in the regulation of ion channels and other processes in the body, as well as its potential as a drug or biomarker for various diseases.

Protein Name: Small Nucleolar RNA, C/D Box 92

The "SNORD92 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD92 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets